<DOC>
	<DOCNO>NCT00814346</DOCNO>
	<brief_summary>The aim study evaluate effect EGb761® , comparison placebo , cerebral glucose metabolism , three group elderly patient : newly diagnose mild Alzheimer 's disease ( AD ) , memory complaint patient cognitive impairment ( MC ) memory complaint patient cognitively normal ( CNE ) . The first phase include four week treatment EGb761® group , change brain glucose metabolism month 1 use 18 FDG-PET , primary endpoint follow open 17 month follow-up ( FU ) period EGb761® treatment MC CNE patient .</brief_summary>
	<brief_title>Effect EGb761® Brain Glucose Metabolism Three Groups Elderly Defined Cognitive Functions</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<criteria>Group Specific Cognitively normal elderly ( CNE ) Spontaneous memory complaint patient , MiniMental State Exam score ≥ 28 . Clinical Dementia Rating = 0 . No Diagnostic And Statistical Manual Of Mental Disorders , Fourth Edition ( DSMIV ) criterion Dementia . Memory complaint ( MC ) : Spontaneous memory complaint patient MiniMental State Exam score ≥ 25 Clinical Dementia Rating 0.5 . No DSMIV criterion Dementia . Mild Alzheimer 's Disease ( AD ) : Mini Mental Status Examination ( MMSE ) 20 28 ( inclusive ) . Clinical Dementia Rating ≥ 1.0 DSMIV criterion Dementia . National Institute Neurological Communicative Diseases Stroke / Alzheimer 's Disease Related Disorders Association ( NINCDS/ADRDA ) criteria probable AD . Newly diagnose patient without treatment Cholinesterase Inhibitors Memantine . ≥ 65 year age , sex Geriatric Depression Scale ( GDS ) &lt; 15 Informed consent sign patient , necessary legal representative Contraindication Magnetic Resonance Imaging ( MRI ) and/or PositronEmission Tomography ( PET ) scan Forbidden Concomitant medication ( Cholinesterase inhibitor memantine , Specific psychoactive medication , e.g. , neuroleptic , chronic anxiolytic include meprobamate , sedative hypnotic benzodiazepine , Monoamine oxidase inhibitor ( MAOIs ) include selective MAOIs . Drugs act cerebral nervous system , Antidiabetes medication , Antioxidants medication , Medications know interfere cognitive evaluation Significant neurological disease psychiatric disorders/psychotic feature Significant medical illness</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Mild Alzheimer 's disease ( AD ) patient</keyword>
	<keyword>Memory complaint patient cognitive impairment ( MC )</keyword>
	<keyword>Memory complaint patient cognitively normal ( CNE )</keyword>
</DOC>